Answers are grounded in this paper and cite their sources.
Bangladesh is experiencing its worst measles outbreak in decades, with more than 50,500 suspected cases and at least 415 confirmed or suspected measles-related deaths during the reporting period from mid-March to mid-May 2026. After years of progress that had sharply reduced measles incidence, this resurgence reflects not a biological inevitability but a preventable systems failure. A nationwide Measles-Rubella (MR) vaccine stockout in 2024 to 2025, the absence of nationwide supplementary immunization activities (SIAs) since 2020, declining MR1 and MR2 coverage, and widening subnational inequities have combined to erode population immunity. The burden has fallen disproportionately on zero-dose and under-vaccinated children in urban slums, hard-to-reach rural areas, and refugee camps, especially infants too young for routine vaccination. Positioned within the broader post-COVID global resurgence, Bangladesh’s epidemic highlights measles as a sentinel of weakening immunization resilience. The crisis underscores three transferable lessons for countries facing declining coverage: maintain buffer stocks and diversified procurement to prevent stockouts, prioritize catch-up SIAs when routine coverage falters, and embed equity-focused outreach to reach zero-dose children before outbreaks occur. This perspective article delves into the structural reforms needed in vaccine governance and procurement, the restoration of routine and catch-up immunization services with equity at their center, and the transparent accountability required to address the failures that created the current immunity gap.
No takes yet. Share an insight, caveat, or question.
Md. Abdus Salam (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: